Please sign in to follow a disease.
Can a fruit compound clear old cells and fight aging?
NCT ID NCT06431932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests fisetin, a natural compound found in strawberries and apples, in healthy young adults and older people with multiple chronic diseases. Participants take fisetin or a placebo for two days and are followed for up to three months. The goal is to see if fisetin safely removes senescent (aging) cells and reduces inflammation, which could help manage age-related health problems.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- fisetin (a natural compound from fruits and vegetables)
- What this could lead to
- If it works, this could point toward a treatment that reduces chronic inflammation and age-related diseases by clearing old, damaged cells.
- What could go wrong
- This is an early Phase 1/2 trial with only 60 participants, so results may not apply broadly. Fisetin's effects on humans are still uncertain, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Healthy volunteers: Inclusion Criteria: * Aged 20-35 years * suPAR levels \<3.5 ng/mL (± 15% corresponding to assay variation) * Able to cooperate cognitively * Able to read and understand Danish * Women of childbearing potential must use effective contraception Exclusion Criteria: * Body weight \>100 kg * Inability to swallow pills * Pregnant and/or lactating * Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules * Presence of any condition that the investigator believes would put the subject at risk or would preclude the participant from successfully completing all aspects of the trial * Presence of known chronic diagnosis * Active acute illness * Prescribed medication, except contraceptives * Previous cancer diagnosis or treatment * Use of senolytic and other "anti-aging" supplements Older patients with multimorbidity: Inclusion Criteria: At screening #1 during hospital admission: * Acutely hospitalized medical patient * Age ≥65 years * suPAR \>5 ng/mL (± 15% corresponding to assay variation) * Multimorbidity (≥2 chronic diagnoses) * Able to cooperate cognitively * Able to read and understand Danish At screening #2 28 days after hospital discharge: * suPAR \>5 ng/mL (± 15% corresponding to assay variation) Exclusion Criteria: At screening #1 during hospital admission: * Body weight \>100 kg * Inability to swallow pills * Known human immunodeficiency virus infection, active hepatitis B or C infection, invasive fungal infection * Uncontrolled (as per clinical judgment) pleural/pericardial effusions or ascites * New/active invasive cancer except non-melanoma skin cancers * Active cancer treatment or disseminated cancer * Known condition associated with major immunodeficiency * Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules * Use of senolytic and other "anti-aging" supplements At screening #2 28 days after hospital discharge: * Body weight \>100 kg * CRP \>30 mg/L (± 15% corresponding to assay variation) * Inability to swallow pills * Presence of any condition, or abnormal routine biochemistry test, that the investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial * Unstable (as per clinical judgment) major disorders, e.g., cardiovascular, renal, endocrine, immunological, hepatic disorder, or cancer * Estimated glomerular filtration rate (eGFR) \<15 ml/min/1.73 m2 or as per clinical judgment (e.g., risk of acute kidney injury) * Human immunodeficiency virus infection, known active hepatitis B or C infection, invasive fungal infection * Uncontrolled (as per clinical judgment) pleural/pericardial effusions or ascites * New/active invasive cancer except non-melanoma skin cancers * Active cancer treatment or disseminated cancer * Known condition associated with major immunodeficiency * Known hypersensitivity or allergy to fisetin or excipients in the placebo capsules * Subjects taking strong inhibitors or inducers of CYP3A4 or as per clinical judgment * Subjects taking specified substrates with a narrow therapeutic range for CYP3A4 or as per clinical judgment * Subjects taking specified inhibitors, inducers, or substrates of CYP2D6, CYP2C9, or CYP2C8, or as per clinical judgment * Subjects regularly using drug classes or specific medications or as per clinical judgment * Use of senolytic and other "anti-aging" supplements
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Clinical Research, Copenhagen University Hospital Amager & Hvidovre
RECRUITINGHvidovre, 2650, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a protein powder with creatine and fiber boost everyday Well-Being?
- Green tech or hidden stress? bus Drivers' hearts monitored behind the wheel
- Shout it out: can growls and screams raise pain tolerance?
- Scientists probe why brain stimulation works for some and not others
- Tiny doses, big questions: how does the body handle this prodrug?
- First human test of CM583: can this biologic pass the safety check?